ClinicalTrials.gg
Not yet recruitingNCT07854639Updated Oct 2, 2026

A Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

A Phase 2 interventional study of Zeprumetostat Tablets in Cutaneous T-Cell Lymphoma/Mycosis Fungoides/Sézary Syndrome, sponsored by Peking University First Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Peking University First Hospital · Phase 2, Interventional, and Treatment

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Lymphoma, T-Cell, Cutaneous with a site in China — 11 open to participants now, 12 under way, none of them phase 3. Lymphoma, T-Cell, Cutaneous · China.

Planned enrollment
11th of 13
33 · median 48
Started
2026
with 1 other
Phase 2
5 of 15
2 open now
Primary completion
2027-12
later than 7 of 11 live
Registered
15th of 15
by date
Lead sponsor
3 of 15
Peking University First Hospital

Among the 15 studies in Lymphoma, T-Cell, Cutaneous with a site in China, this one is the 11th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 in phase 2, reaches primary completion later than 7 of the 11 other live ones, and was the 15th registered.

Lymphoma, T-Cell, Cutaneous

554 studies on the registry are indexed under Lymphoma, T-Cell, Cutaneous; 63 are open to participants now.

Browse Lymphoma, T-Cell, Cutaneous studies →

Open to participants now

11 of the 15 studies in Lymphoma, T-Cell, Cutaneous with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Lymphoma, T-Cell, Cutaneous studies recruiting now, 33 (75%) set no upper age limit and 6 (14%) stop at 75 or younger; 5 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Lymphoma, T-Cell, Cutaneous with a site in China, or all of them as a file.
02

Study summary

Patients with relapsed or refractory cutaneous T-cell lymphoma (R/R CTCL) face a poor prognosis and limited therapeutic options. Advanced or relapsed disease yields a 5-year overall survival rate of \<50%. Real-world data show that third-line therapy achieves an ORR of only 45-50% with a median PFS of 1.2 years. Chemotherapy remains dominant (43.1% in the third-line) but offers limited, transient efficacy (median time to next treatment: 4 months) and severe toxicities, leaving a critical unmet need for safe, highly specific targeted therapies.

Epigenetic dysregulation is central to CTCL pathogenesis, particularly aberrations in the histone methyltransferase EZH2. As the catalytic subunit of PRC2, EZH2 mediates H3K27me3 to repress target gene transcription. In CTCL, EZH2 frequently undergoes copy number amplification or gain-of-function mutations to drive tumor progression. Targeting EZH2 demonstrates high tumor specificity; EZH2 inhibitors like tazemetostat and valemetostat are already approved for epithelioid sarcoma, follicular lymphoma, and peripheral T-cell lymphoma (PTCL). Preclinically, EZH2 is specifically overexpressed in neoplastic CTCL T cells, and EZH2 inhibitors dose-dependently suppress CTCL cell/tumor growth.

Given shared pathogenic mechanisms, PTCL data provide strong reference for CTCL. Valemetostat achieved an ORR of 43.7% and median PFS of 5.5 months in R/R PTCL. Zeprumetostat demonstrated superior efficacy (ORR 61%, median PFS 11.1 months) with a favorable safety profile, leading to its 2025 approval in China for R/R PTCL.

Therefore, this single-arm, prospective trial evaluates zeprumetostat in R/R CTCL. Given that CTCL shares essential pathogenetic and epigenetic features with PTCL, and leveraging zeprumetostat's established approval in PTCL, this study represents a rational and mechanistically justified therapeutic expansion rather than an unsupported off-label application.

03

Conditions studied

  • Cutaneous T-Cell Lymphoma/Mycosis Fungoides/Sézary Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years, regardless of sex;
  2. Mycosis fungoides or Sézary syndrome confirmed by histopathological examination;
  3. Patients with , with or without extracutaneous involvement, and clinical stage IIB-IVB;
  4. Patients with no response or relapse after remission following at least one (including total-skin electron-beam irradiation, bexarotene, retinoids, interferons, extracorporeal photopheresis, methotrexate, chidamide, etc.);
  5. Adequate major organ function, meeting the following criteria: a) Serum total (TBIL) ≤ 1.5 × (ULN) in patients without liver ; b) (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; c) Creatinine (Cr) ≤ 1.5 × ULN, or (Ccr) ≥ 50 mL/min (calculated by the Cockcroft-Gault formula);
  6. Adequate bone marrow function: (ANC) ≥ 1.5 × 10\^9/L, count (PLT) ≥ 80 × 10\^9/L, and (HGB) ≥ 90 g/L;
  7. performance status ≤ 2;
  8. Willingness not to participate in other interventional studies during the treatment period;
  9. Voluntary provision of written , understanding of the nature, purpose, and procedures of the study, and willingness to comply with the study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with an EZH2 inhibitor or an EZH1/2 inhibitor;
  2. Dysphagia or inability to receive oral medication due to gastrointestinal disorders;
  3. History of other primary invasive that are not resolved or have been in remission for ≤ 3 years;
  4. Known to any medication used in the study;
  5. Participation in other drug clinical trials within 4 weeks prior to study initiation;
  6. Concomitant use of known moderate or strong or CYP3A5 inducers/inhibitors, or P-gp inhibitors;
  7. History of immunodeficiency, including positive test, other acquired or congenital immunodeficiency diseases, or history of organ transplantation;
  8. Patients who have undergone major surgery within 4 weeks prior to enrollment and have not fully recovered;
  9. Chronic respiratory disease requiring continuous oxygen therapy; history of renal, neurological, psychiatric, endocrine, metabolic, immune, hepatic (decompensated cirrhosis class B or C), or cardiovascular diseases; or any other disease that, in the investigator's judgment, may adversely affect the patient's participation in this study;
  10. Active, uncontrolled infections, including but not limited to: active (defined as positive HBsAg AND HBV DNA ≥ 2000 IU/mL AND ≥ 2 × , with drug-induced or other causes of hepatitis excluded), (defined as positive anti-HCV antibody AND positive HCV RNA), human immunodeficiency virus (HIV) infection, or positive syphilis-specific antibody test;
  11. Pregnant or lactating women, or female patients planning to become pregnant during the study;
  12. History of stroke or intracranial hemorrhage within ≤ 6 months prior to the first dose of the study drug;
  13. Any other condition that, in the opinion of the investigator, makes the patient unsuitable for inclusion in the study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Experimental Arm

    Patients receive EZH2 inhibitor Zeprumetostat Tablets monotherapy

    Drug: Zeprumetostat Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate maintained for at least 4 months (ORR4)

    The percentage of patients achieving a complete response (CR) or partial response (PR) that is maintained for at least 4 months.

    Time frame: From baseline until disease progression, death, or start of new anticancer therapy, assessed up to 24 treatment cycles (approximately 22-24 months).

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identifed individual participant data including baseline characteristics, efficacy and safety outcome data willbe shared after study completion and primary publication.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: De-identified IPD and supporting documents will become available 12 months after the publication of the primary study results and will remain accessible indefinitely to eligible researchers upon approved application.

Access criteria: Qualifed researchers may submit a formal research proposal and data use agreementto the study principal investigator. Proposals wil be reviewed for scientific validity prior to data access approval.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2027, 13 months later.

Of 34 non-industry phase 2 interventional studies under Lymphoma, T-Cell, Cutaneous, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 111. This study's planned 13 months is below that.

Counting every sponsor, half of 47 studies reached it within 64 months; a quarter within 36 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 2, 2026
StartEst.
Oct 31, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
May 30, 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854639
Responsible party
Yang WANG (Professor, Chief Physician, Peking University First Hospital) — Principal investigator
First posted
Oct 2, 2026
Start date
Oct 31, 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
May 30, 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Wang Yang
Contact
yangwang_dr@bjmu.edu.cn
+86 18610381256

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zeprumetostat

Start the discussion